How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?

Do you offer observation for POLE mutated tumors?

Answer from: at Academic Institution

We have a paper coming out next month showing that carcinosarcomas (UCS) that have POLE mutations do much better than the other subtypes and are statistically equivalent to survival of POLE endometrioid tumors. Having said that, I do not believe there is enough data to de-escalate POLE UCS and would...

Comments

Radiation Oncologist at Sanford Health
EORTC 55874 was a study of uterine sarcoma. A uter...

at University of Alabama at Birmingham
There was equal distribution between carcinosarcom...

Answer from: Radiation Oncologist at Community Practice

I would not change the management of IB and above non-endometrioid histology based on mutation analysis as almost all data is for endometrioid histology.

Answer from: Radiation Oncologist at Academic Institution

No data I am aware of for POLE status portending for better prognosis in non-endometrioid histologies. For this patient, I would treat as per our institutional (and NCCN-supported) standard, which is chemotherapy + cuff brachytherapy.

Please select the option that best describes you:

How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?

Related Questions